Skip to content Skip to footer
VIEWPOINTS_Andrew Menzies-Gow2_2024

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]